Edition:
United States

Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

6,090JPY
2:00am EDT
Change (% chg)

¥-1 (-0.02%)
Prev Close
¥6,091
Open
¥6,089
Day's High
¥6,113
Day's Low
¥6,071
Volume
3,626,000
Avg. Vol
1,892,778
52-wk High
¥6,199
52-wk Low
¥4,321

Select another date:

Tue, Aug 29 2017

Photo

AstraZeneca strikes $400 million Parkinson's drug deal with Takeda

LONDON AstraZeneca is to receive up to $400 million from Takeda Pharmaceutical after striking a deal for the Japanese company to co-develop an early-stage medicine for Parkinson's disease.

AstraZeneca strikes $400 mln Parkinson's drug deal with Takeda

LONDON, Aug 29 AstraZeneca is to receive up to $400 million from Takeda Pharmaceutical after striking a deal for the Japanese company to co-develop an early-stage medicine for Parkinson's disease.

Samsung Bioepis teams up with Takeda to develop original biotech drugs

SEOUL Samsung Bioepis Co Ltd said on Monday it will fund and develop multiple original drugs in partnership with Japan's Takeda Pharmaceutical Co Ltd, expanding its business scope beyond copies of existing biologic drugs.

Samsung Bioepis teams up with Takeda to develop original biotech drugs

* Bioepis' Enbrel copy generated over $250 mln in sales since 2016

BRIEF-Takeda Pharmaceutical Co reports 10.9 pct stake in Molecular Templates - SEC Filing‍​

* Takeda Pharmaceutical Company reports 10.9 percent stake in Molecular Templates Inc as of August 1, 2017 - SEC Filing‍​ Source text: (http://bit.ly/2vTAtQL) Further company coverage:

BRIEF-Takeda and Shattuck Labs announce research collaboration

* Takeda and Shattuck Labs announce research collaboration to explore agonist redirected checkpoint fusion proteins in immuno-oncology

BRIEF-Takeda and Cardurion Pharmaceuticals launch cardiovascular development partnership

* Takeda and Cardurion Pharmaceuticals launch cardiovascular development partnership

UPDATE 1-Japanese drugmaker Takeda posts stronger profit as U.S. sales jump

* Astellas Q1 operating profit halves from year ago (Adds wider industry context, Astellas results)

BRIEF-Takeda, Schrödinger announce multi-year, multi-target research collaboration

* Takeda and Schrödinger announce multi-year, multi-target research collaboration

U.S. court upholds Takeda patent on cancer drug Velcade

A U.S. appeals court ruled on Monday that a patent on Takeda Pharmaceutical Co Ltd's cancer treatment Velcade is valid, pushing back the date when generic drug makers including Teva Pharmaceutical Industries Ltd and Mylan NV will be allowed to launch lower-cost versions of the drug in the United States.

Select another date: